Clinical Trials Browser

INDUSTRY × pexidartinib × Clear all

NCT04703322 2026-03-04

A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Phase 2 Active not recruiting

9 enrolled 10 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT02975700 2026-01-13

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

Phase NA Completed

6 enrolled 21 charts

Melanoma

NCT04635111 2025-10-06

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

Giant Cell Tumor of Tendon Sheath

NCT04488822 2025-09-09

PLX3397

Phase 3 Active not recruiting

40 enrolled 15 charts

Giant Cell Tumor of Tendon Sheath

NCT02401815 2025-02-14

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

Phase 1/2 Completed

51 enrolled 32 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04526704 2024-12-30

PLX3397

Phase 4 Completed

32 enrolled 15 charts

Giant Cell Tumor of Tendon Sheath

NCT02371369 2022-05-11

ENLIVEN

Phase 3 Completed

120 enrolled 25 charts 1 FDA

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT02734433 2022-04-25

Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors

Phase 1 Completed

12 enrolled 22 charts

Other solid neoplasm

Advanced Solid Tumors

NCT01004861 2022-01-04

Safety Study of PLX108-01 in Patients With Solid Tumors

Phase 1 Completed

132 enrolled 28 charts

Other solid neoplasm

Solid Tumor

NCT04223635 2021-06-22

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Phase EARLY_PHASE1 Completed

16 enrolled 22 charts

Giant Cell Tumor of Tendon Sheath

NCT03291288 2021-05-14

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Phase 1 Completed

32 enrolled 22 charts

Synovitis, Pigmented Villonodular

NCT01217229 2020-06-30

Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

20 enrolled 7 charts

Hodgkin Disease

NCT01790503 2020-06-30

A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma

Phase 1/2 Completed

65 enrolled 26 charts

Glioblastoma

NCT02452424 2020-03-05

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Phase 1/2 Terminated

78 enrolled 19 charts

DermatologicGastrointestinalGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Gastrointestinal Stromal Tumors

NCT01499043 2020-03-04

Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

Phase 2 Terminated

6 enrolled 6 charts

Prostatic Neoplasms

NCT01349049 2020-03-02

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1/2 Completed

90 enrolled 23 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute